Fenoverine | CAS#37561-27-6 | biochemical

MedKoo Cat#: 146389 | Name: Fenoverine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fenoverine is an antispasmodic drug primarily used to relieve gastrointestinal discomfort associated with conditions like irritable bowel syndrome and biliary colic. It works by inhibiting calcium influx into smooth muscle cells, thereby reducing muscle contractions and alleviating spasms. Unlike anticholinergic agents, fenoverine acts directly on smooth muscle without affecting autonomic neurotransmission.

Chemical Structure

Fenoverine

CAS#37561-27-6

Theoretical Analysis

MedKoo Cat#: 146389

Name: Fenoverine

CAS#: 37561-27-6

Chemical Formula: C26H25N3O3S

Exact Mass: 459.1617

Molecular Weight: 459.56

Elemental Analysis: C, 67.95; H, 5.48; N, 9.14; O, 10.44; S, 6.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Fenoverine;

IUPAC/Chemical Name

2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-1-(10H-phenothiazin-10-yl)ethan-1-one

InChi Key

UBAJTZKNDCEGKL-UHFFFAOYSA-N

InChi Code

1S/C26H25N3O3S/c30-26(29-20-5-1-3-7-24(20)33-25-8-4-2-6-21(25)29)17-28-13-11-27(12-14-28)16-19-9-10-22-23(15-19)32-18-31-22/h1-10,15H,11-14,16-18H2

SMILES Code

O=C(CN1CCN(CC2=CC3=C(OCO3)C=C2)CC1)N4C5=CC=CC=C5SC6=CC=CC=C46

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 459.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chariot P, Ratiney R, Le Maguet F, Fourestié V, Astier A, Gherardi R. Fenoverine-induced rhabdomyolysis. Hum Exp Toxicol. 1995 Aug;14(8):654-6. doi: 10.1177/096032719501400805. PMID: 7576832. 2: Mironneau J, Arnaudeau S, Mironneau C. Fenoverine inhibition of calcium channel currents in single smooth muscle cells from rat portal vein and myometrium. Br J Pharmacol. 1991 Sep;104(1):65-70. doi: 10.1111/j.1476-5381.1991.tb12386.x. PMID: 1786520; PMCID: PMC1908293. 3: Mousavi T, Sharifnia M, Nikfar S, Abdollahi M. Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2021-2033. doi: 10.1080/14656566.2023.2265830. Epub 2024 Jan 5. PMID: 37788098. 4: Bader F. Fenoverine: a two-step, double-blind and open clinical assessments of its smooth muscle synchronizing effects. Pharmatherapeutica. 1986;4(7):422-8. PMID: 3515369. 5: Gonella J, Lalanne C, Mironneau J. Fenoverine: a novel synchronizer of smooth muscle motility by interference with cellular calcium flow. Curr Med Res Opin. 1987;10(7):427-35. doi: 10.1185/03007998709112400. PMID: 3113828. 6: Lira-Plascencia J, Arzola-Paniagua A, Carranza-Lira S. Fenoverine vs. mefenamic acid in the treatment of primary dysmenorrhea. Int J Gynaecol Obstet. 2006 Apr;93(1):72-3. doi: 10.1016/j.ijgo.2006.01.006. Epub 2006 Mar 9. PMID: 16524578. 7: Camarri E. Fenoverine: smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation. Curr Med Res Opin. 1986;10(1):52-7. doi: 10.1185/03007998609111090. PMID: 3516580. 8: Cho J, Na J, Bae E, Lee TW, Jang HN, Cho HS, Chang SH, Park DJ. The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999-2014). BMC Pharmacol Toxicol. 2020 Apr 25;21(1):30. doi: 10.1186/s40360-020-00408-3. PMID: 32334639; PMCID: PMC7183697. 9: Chen CW, Chang MH. Rhabdomyolysis induced by fenoverine: a case report and literature review. Acta Neurol Taiwan. 2005 Sep;14(3):143-6. PMID: 16252617. 10: Kang SH, Jeen YT, Koo JS, Koo YS, Kim KO, Kim YS, Kim SY, Moon JS, Park JJ, Baek IH, Park SC, Lee SJ, Lee JH, Choung RS, Choi SC. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. Korean J Gastroenterol. 2013 Nov;62(5):278-87. Korean. doi: 10.4166/kjg.2013.62.5.278. PMID: 24262593. 11: Jouglard J, Kozak-Ribbens G, de Haro L, Cozzone PJ. Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine. Hum Exp Toxicol. 1996 Oct;15(10):815-20. doi: 10.1177/096032719601501004. PMID: 8906430. 12: Sultan S, Lesgourgues B, el Attar Y, Fauvelle F, Delas N. Rhabdomyolyse aiguë à la fénovérine (Spasmopriv). Un cas et revue de la littérature [Acute rhabdomyolysis due to fenoverine (Spasmopriv). A case and review of the literature]. Therapie. 1992 Sep-Oct;47(5):443. French. PMID: 1299995. 13: De Santis D, Marrazzo R, Losasso C, Loffreda A, De Paola C, De Novellis V, Molinario L, Schiariti F, Marmo E. Pharmacodynamic profile of fenoverine, a novel modulator of smooth muscle motility. Drugs Exp Clin Res. 1989;15(1):37-42. PMID: 2743871. 14: Bandari S, Eaga CM, Thadishetty A, Yamsani MR. Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine. Acta Pharm. 2010 Mar;60(1):89-97. doi: 10.2478/v10007-010-0001-3. PMID: 20228043. 15: Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007 Nov;33(11):1225-32. doi: 10.1080/03639040701377888. PMID: 18058319. 16: Hu OY, Chen PH, Fang YJ, Tang HS, Pao LH, Kwok KM, King ML. Determination of fenoverine, a modulator of smooth muscle motility, in capsules and in human plasma: application to dosage form stability and a pilot study in humans. J Pharm Sci. 1992 Jan;81(1):91-3. doi: 10.1002/jps.2600810118. PMID: 1619577. 17: Ratiney R, Astier A, Chariot P. Determination of fenoverine in tissue samples by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):159-63. doi: 10.1016/0378-4347(94)00016-6. PMID: 8004239. 18: Ouakil H, Pouchot J, Debin ML, Le Bourdelles G, Coste F, Vinceneux P. Rhabdomyolyse aiguë due à la fénoverine [Acute rhabdomyolysis caused by fenoverine]. Rev Med Interne. 1994;15(10):695-6. French. doi: 10.1016/s0248-8663(05)82187-3. PMID: 7800993. 19: Costa R, Cirrincione M, Cangialosi G, Chinnici M, Salerno V, Mannino R, Scaffidi L, Scaffidi A. Effetti della fenoverina sulla cinetica biliare valutata con scintigrafia epatobiliare con 99mTc-Br-IDA [Effects of fenoverine on biliary kinetics evaluated by hepatobiliary scintigraphy with 99mTc-Br-IDA]. Minerva Med. 1992 Jun;83(6):355-8. Italian. PMID: 1630696. 20: Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez- Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012 Apr- Jun;77(2):82-90. doi: 10.1016/j.rgmx.2012.04.002. Epub 2012 Jun 5. PMID: 22672854.